Analyst Brandon Folkes of H.C. Wainwright reiterated a Buy rating on PolyPid, retaining the price target of $13.00.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Brandon Folkes has given his Buy rating due to a combination of factors that highlight PolyPid’s promising future. The company has made significant progress with its D-PLEX100 product, which is on track for an NDA submission in early 2026 following positive Phase 3 trial results. This product demonstrated a substantial reduction in surgical site infections, showcasing its efficacy and safety.
Beyond D-PLEX100, PolyPid is advancing its drug delivery technology, which has the potential to expand into a pipeline of products, including a long-acting GLP-1 delivery platform targeting obesity and diabetes. The company’s successful regulatory inspections and ongoing U.S. partnership discussions further validate its operational strength. With a market cap of $60M, PolyPid offers a favorable risk-reward profile, supported by its cash reserves projected to fund operations well into 2026.